查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2003957

一氧化氮吸入市場：按產品、分銷管道、應用和最終用戶分類－2026-2032年全球市場預測

Inhaled Nitric Oxide Market by Product, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，吸入式一氧化氮市場價值將達到 8.7137 億美元，到 2026 年將成長至 9.1753 億美元，到 2032 年將達到 13.1361 億美元，年複合成長率為 6.03%。

主要市場統計數據
基準年 2025 8.7137億美元
預計年份：2026年 9.1753億美元
預測年份 2032 131361億美元
複合年成長率 (%) 6.03%

本文全面說明了吸入一氧化氮療法在新生兒和成人呼吸照護環境中的臨床作用、給藥方法和策略意義。

吸入一氧化氮（iNO）已從一種小眾治療方法發展成為多種急性慢性肺部疾病的關鍵輔助治療。它作為一種快速起效、半衰期短的選擇性肺血管擴張劑，在需要快速調節肺血管阻力和氧合的臨床環境中具有重要的效用。臨床醫生和醫療系統領導者越來越將iNO視為傳統治療方法不足以有效治療呼吸衰竭時的重要呼吸支持工具，這引起了醫院管理者、呼吸治療團隊和採購部門的廣泛關注。

技術進步、監管調整和供應彈性措施如何改變吸入一氧化氮的臨床引入和籌資策略。

近年來，吸入一氧化氮領域經歷了多項變革性變化，正在重塑臨床應用和供應鏈的動態。給藥技術的進步使得更緊湊、整合化的發生器和攜帶式氣瓶解決方案成為可能，從而縮短了床邊設置時間，並拓展了其在門診和居家照護環境中的應用範圍。除了技術進步之外，臨床通訊協定的擴展以及吸入一氧化氮在難治性低氧血症和肺動脈高壓等情況下的接受度不斷提高，也促使醫療採購的重點轉向可靠的按需供應模式。

評估 2025 年美國關稅變化對吸入式一氧化氮的採購和供應鏈彈性規劃的營運和採購影響。

美國2025年實施的關稅調整對吸入式一氧化氮產品及相關硬體的採購、定價結構和供應鏈規劃產生了複雜的連鎖反應。進口關稅和海關程序的調整增加了某些進口零件和整套交付系統的成本，迫使製造商和經銷商重新評估籌資策略和庫存管理實踐。在此背景下，關鍵製造流程盡可能地外包，同時，為了適應到貨成本和前置作業時間的變化，供應合約也進行了重新談判。

基於細分市場的詳細洞察，解釋了產品形式、臨床應用、最終用戶環境和分銷管道如何決定採購和臨床部署選擇。

細分市場分析揭示了產品選擇、臨床應用、終端用戶偏好和通路的關鍵差異，這些差異共同有助於制定部署和營運計劃。按產品類型分類，市場細分為氣瓶、產生器和儲罐，每種形式對儲存、床邊工作流程和維護要求都有其獨特的影響。氣瓶適用於快速部署和小規模醫療機構；產生器可實現整合劑量控制，適用於用量大的機構；儲槽則非常適合服務多家機構的集中供應模式。基於應用領域，市場分析涵蓋成人肺動脈高壓、急性呼吸窘迫症候群 (ARDS) 和新生兒肺動脈高壓。成人肺動脈高壓細分市場進一步分為特發性和續發性，反映了不同的診斷路徑、合併症情況和長期管理策略。 ARDS細分市場進一步分為體外膜氧合 (ECMO) 和侵入性通氣 (IVV)，展示了吸入一氧化氮 (iNO) 如何與先進的呼吸支持方法相結合。新生兒肺動脈高壓市場進一步細分為體外膜肺氧合（ECMO）和機械通氣（MV），突顯了新生兒專用工作流程和設備相容性的重要性。按最終用戶分類，市場可分為門診手術中心、居家醫療、醫院和專科診所，每種用戶對庫存管理通訊協定、人員配備和供應合約模式的要求各不相同。按分銷管道分類，市場可分為直接競標、分銷合作夥伴和線上管道，這些管道在預期前置作業時間時間、合約結構以及產品提供的技術和臨床支援程度方面存在差異。

美洲、歐洲、中東、非洲和亞太地區在臨床基礎設施、採購慣例和法規方面的區域差異如何塑造差異化的策略。

區域趨勢持續影響吸入式一氧化氮領域的臨床部署重點、供應鏈結構和監管參與。在美洲，從大規模擴充性醫療機構到地方醫院，醫療保健體系的多樣性凸顯了兩種需求：一是滿足醫院高容量使用需求的可擴展發生器解決方案，二是滿足社區和居家醫療項目需求的攜帶式氣瓶。支付方結構和醫療保健採購慣例對該地區的合約策略和產品協議中包含的支持力度有顯著影響。

影響供應商選擇和採購決策的競爭差異因素概述：供應方式創新、優質服務和策略性經銷夥伴。

該領域的競爭動態反映了技術創新、服務模式差異化和策略性經銷夥伴的綜合作用。主要企業正投資於能夠減少臨床操作摩擦的給藥平台，具體措施包括簡化設定、明確劑量管理以及整合監測，以支援文件記錄和品質保證。同時，各企業正透過售後服務模式實現差異化，例如維護合約、臨床教育計畫和遠端支持，以確保持續運作並遵循最佳實踐通訊協定。

為相關人員提供切實可行的建議，以協調產品創新、供應彈性、臨床支援和分銷策略，從而加快產品部署並減少實施過程中的摩擦。

產業領導企業應採取整合策略，同時兼顧臨床、營運和商業層面。首先，應優先投資於能夠簡化臨床工作流程並在各種醫療環境中提供可靠性能的交付平台。易用性和與監測系統的互通性可減輕訓練負擔，並降低更廣泛部署的門檻。其次，應制定穩健的供應鏈彈性計劃，包括採購管道多元化、達成本地庫存保障協議以及製定清晰的緊急應變通訊協定，以減輕貿易中斷和運輸延誤的影響。

透過高度透明的調查方法，結合關鍵相關人員的訪談和二手臨床及監管訊息，從多個角度檢驗臨床和採購領域的見解。

本分析的調查方法融合了定性和定量方法，旨在從實證角度深入了解臨床實踐、採購趨勢和產品部署。主要研究包括對臨床醫生、呼吸治療師、採購負責人和分銷主管進行結構化訪談，以收集有關設備可用性、供應鏈挑戰以及與臨床通訊協定整合等方面的實際資訊。此外，也參考了同儕審查的臨床文獻、監管指導文件和已發布的臨床實踐標準等二手資料，以公認的醫學證據為基礎，探討設備及其應用。

結論強調以臨床醫生為中心的設計、供應彈性以及協作部署策略是持續獲得吸入一氧化氮療法的基礎。

吸入一氧化氮（iNO）仍然是多種嚴重呼吸系統疾病治療中不可或缺且用途廣泛的輔助性治療，其有效實施需要根據實際臨床情況調整產品設計、臨床通訊協定和供應策略。儘管臨床進展和給藥方法的創新正在拓展iNO的應用範圍和方法，但採購和監管趨勢正日益影響其可及性和營運準備。那些採取綜合方法，整合技術選擇、臨床醫生培訓和供應保障的機構，更有能力確保患者獲得不間斷的治療，並最大限度地發揮該療法的臨床益處。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 吸入式一氧化氮市場：依產品分類

  • 圓柱
  • 發電機
  • 油船

第9章 吸入用一氧化氮市場：依分銷管道分類

  • 直接競標
  • 銷售合作夥伴
  • 線上

第10章 吸入式一氧化氮市場：依應用領域分類

  • 成人肺動脈高壓
    • 特發性
    • 次要
  • ARDS
    • 體外膜氧合（ECMO）
    • 侵入性通氣
  • 新生兒肺動脈高壓
    • 體外膜氧合（ECMO）
    • 人工呼吸

第11章 吸入式一氧化氮市場：依最終用戶分類

  • 線上
  • 離線

第12章 吸入式一氧化氮市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 吸入式一氧化氮市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 吸入用一氧化氮市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國一氧化氮吸入市場

第16章：中國一氧化氮吸入市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Air Liquide SA
  • BOC Ltd.
  • Circassia Pharmaceuticals plc
  • Ikaria, Inc.
  • Linde plc
  • Mallinckrodt plc
  • Messer Group GmbH
  • Novoteris, LLC
  • Praxair, Inc.
  • VERO Biotech LLC
Product Code: MRR-2D668742FD36

The Inhaled Nitric Oxide Market was valued at USD 871.37 million in 2025 and is projected to grow to USD 917.53 million in 2026, with a CAGR of 6.03%, reaching USD 1,313.61 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 871.37 million
Estimated Year [2026] USD 917.53 million
Forecast Year [2032] USD 1,313.61 million
CAGR (%) 6.03%

A comprehensive introduction to inhaled nitric oxide that frames its clinical role, delivery modalities, and strategic relevance across neonatal and adult pulmonary care settings

Inhaled nitric oxide (iNO) has evolved from a niche therapeutic into a critical adjunctive intervention across several acute and chronic pulmonary conditions. Its role as a selective pulmonary vasodilator with rapid onset and short half-life underpins its clinical utility in environments where rapid modulation of pulmonary vascular resistance and oxygenation are required. Clinicians and health system leaders increasingly view iNO as an essential tool for targeted respiratory support when conventional therapies are insufficient, driving interest from hospital administrators, respiratory therapy teams, and procurement functions alike.

As therapeutic pathways converge between neonatal intensive care, adult critical care, and specialized pulmonary programs, stakeholders are seeking deeper understanding of how product formats, delivery platforms, and distribution channels influence clinical workflows and operational readiness. This report centers on product-level differentiation across cylinder, generator, and tanker formats, and how these delivery modalities interact with application-specific protocols from neonatal pulmonary hypertension to acute respiratory distress management in adults. By integrating clinical, logistical, and payer-facing perspectives, the introduction underscores the product's clinical rationale, real-world deployment scenarios, and the strategic considerations that decision-makers must weigh when incorporating iNO into care pathways.

How technological advances, regulatory adjustments, and supply resilience initiatives are collectively reshaping clinical adoption and procurement strategies for inhaled nitric oxide

Recent years have produced several transformative shifts in the inhaled nitric oxide landscape that are reshaping clinical adoption and supply chain dynamics. Advances in delivery technology have enabled more compact, integrated generators and portable cylinder solutions, reducing bedside set-up times and expanding suitability for ambulatory and homecare contexts. Parallel to technological improvements, expanding clinical protocols and broader acceptance of iNO in refractory hypoxemia and pulmonary hypertension scenarios have shifted institutional procurement priorities toward reliable, on-demand supply models.

Regulatory and reimbursement developments have also influenced clinical decision-making, prompting providers to re-evaluate treatment algorithms and to invest in staff training and infrastructure. Strategic partnerships between clinical teams and distribution partners have emerged as a key mechanism to mitigate supply volatility and ensure continuity of care. In addition, a greater emphasis on interoperability and data integration has encouraged manufacturers to incorporate usage-tracking features into devices, supporting quality assurance and facilitating discussions with payers and health systems about appropriate utilization and protocols. Taken together, these shifts are creating a landscape in which clinical effectiveness, delivery flexibility, and supply resilience are increasingly interdependent.

Assessing the operational and procurement consequences of U.S. tariff changes in 2025 that prompted sourcing shifts and supply chain resilience planning for inhaled nitric oxide

The introduction of tariff changes in the United States in 2025 created a complex ripple effect across procurement, pricing structures, and supply chain planning for inhaled nitric oxide products and associated hardware. Import duties and customs adjustments increased the cost of certain imported components and finished delivery systems, prompting manufacturers and distributors to reassess sourcing strategies and inventory practices. This environment encouraged accelerated nearshoring of key manufacturing steps where feasible, as well as renegotiation of supply agreements to accommodate altered landed costs and lead times.

Hospitals and health systems responded by intensifying collaboration with distribution partners to secure longer-term supply contracts and contingency provisions. Clinical teams incorporated supply risk assessments into therapy selection discussions, prioritizing devices and formats that could be supported reliably under altered trade conditions. At the same time, purchasers considered total cost of ownership across cylinder, generator, and tanker options, factoring in inventory holding, transportation constraints, and training requirements. These strategic adaptations reduced exposure to isolated tariff-driven disruptions and enhanced continuity of care, while highlighting the importance of flexible contracting, multi-supply sourcing, and inventory visibility in maintaining access to critical inhaled nitric oxide therapies.

Detailed segmentation-driven insights explaining how product formats, clinical applications, end-user environments, and distribution channels determine procurement and clinical deployment choices

Segmentation analysis reveals critical distinctions in product choice, clinical application, end-user preferences, and distribution pathways that together inform adoption and operational planning. Based on Product, the market is studied across Cylinder, Generator, and Tanker, and each format brings unique implications for storage, bedside workflow, and maintenance requirements; cylinders support rapid deployment and smaller institutions, generators enable integrated dosing controls suited to high-volume centers, and tankers are optimal for centralized supply models serving multiple facilities. Based on Application, the market is studied across Adult Pulmonary Hypertension, ARDS, and Neonatal Pulmonary Hypertension. The Adult Pulmonary Hypertension segment is further studied across Idiopathic and Secondary, reflecting divergent diagnostic pathways, comorbidity profiles, and long-term management strategies. The ARDS segment is further studied across Extracorporeal Membrane Oxygenation and Invasive Ventilation, illustrating how iNO integrates with advanced respiratory support modalities. The Neonatal Pulmonary Hypertension segment is further studied across Extracorporeal Membrane Oxygenation and Mechanical Ventilation, underscoring the specialized neonatal workflows and device compatibility needs. Based on End User, the market is studied across Ambulatory Surgical Centers, Homecare, Hospitals, and Specialty Clinics, with each setting demanding different inventory protocols, staff competencies, and contractual models for supply. Based on Distribution Channel, the market is studied across Direct Tender, Distribution Partner, and Online, and these channels differ in lead time expectations, contract structure, and the degree of technical and clinical support bundled with the product.

Taken together, segmentation clarifies why product selection and procurement strategies cannot be generalized across all care settings. A hospital operating multiple intensive care units will prioritize generator platforms with integrated monitoring and service agreements, whereas homecare programs will prefer compact cylinder solutions with clear training and telemonitoring support. Distribution preferences also vary: direct tenders often suit large integrated delivery networks seeking price and service guarantees, distribution partners provide logistics expertise and breadth of product access for regional systems, and online channels create opportunities for rapid replenishment for smaller clinics and outpatient programs. These nuances demand distinct commercial approaches and tailored clinical support models for manufacturers and suppliers seeking durable adoption across the care continuum.

How regional clinical infrastructure, procurement practices, and regulatory diversity shape differentiated strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics continue to shape priorities for clinical adoption, supply chain configuration, and regulatory engagement within the inhaled nitric oxide landscape. The Americas feature a diverse set of care settings ranging from large tertiary centers to rural hospitals, prompting a dual emphasis on scalable generator solutions for high-volume hospitals and portable cylinder options for community and homecare programs. In this region, payer structures and institutional procurement practices strongly influence contracting strategies and the degree of support bundled with product agreements.

Europe, Middle East & Africa present a complex tapestry of regulatory frameworks and delivery models that favor adaptable supply strategies. In some countries centralized procurement and national guidelines drive rapid uptake and standardized protocols, while in others fragmented systems create opportunity for distribution partners to deliver localized service and training. Differences in critical care capacity and neonatal care infrastructure across this combined region necessitate flexible delivery formats that can be adapted to varied clinical needs and facility capabilities.

Asia-Pacific remains a region of rapid infrastructure investment and evolving clinical protocols, with significant heterogeneity between mature urban centers and emerging regional hospitals. Growing critical care capacity and expanding neonatal services are increasing demand for both portable and integrated delivery systems. Manufacturers and suppliers that align product design with local regulatory requirements, training infrastructure, and logistical realities are positioned to support improved access while navigating diverse reimbursement and procurement environments across the three major regions.

An overview of competitive differentiation where delivery innovation, service excellence, and strategic distribution partnerships drive supplier preference and procurement decisions

Competitive dynamics in this sector reflect a combination of technological innovation, service model differentiation, and strategic channel partnerships. Leading providers are investing in delivery platforms that reduce clinical friction-simpler setup, clearer dosing controls, and integrated monitoring that supports documentation and quality assurance. At the same time, companies are differentiating through after-sales service models that include maintenance contracts, clinical education programs, and remote support to ensure continuous operation and adherence to best-practice protocols.

Partnerships between manufacturers and distribution partners have become a cornerstone of commercial strategy, enabling broader geographic reach and more reliable logistics support. Suppliers that align with clinical stakeholders by offering structured training, evidence packages, and adaptable financing options gain preferred status with major hospital systems and neonatal networks. Intellectual property around delivery systems and proprietary gas formulations remains important, but the combination of clinical support, supply resilience, and device usability is increasingly decisive in procurement discussions. New entrants that demonstrate strong service capabilities and compliance with regional regulatory requirements can disrupt traditional supplier relationships, particularly in regions where infrastructure investment is accelerating.

Actionable recommendations for stakeholders to align product innovation, supply resilience, clinical support, and distribution strategies to accelerate adoption and reduce deployment friction

Industry leaders should pursue an integrated strategy that addresses clinical, operational, and commercial dimensions simultaneously. First, prioritize investment in delivery platforms that simplify clinical workflows and enable reliable performance across diverse care settings; ease of use and interoperability with monitoring systems reduce training burdens and lower the threshold for broader adoption. Second, establish robust supply resilience plans, including diversified sourcing, local stocking agreements, and clear contingency protocols to mitigate the impact of trade disruptions and transportation delays.

Third, develop comprehensive clinical support packages that include education, implementation guidance, and post-deployment monitoring to demonstrate value to clinicians and procurement teams. Fourth, tailor distribution and contracting approaches to end-user profiles: direct tenders for large systems, distribution partnerships for regional coverage, and online replenishment options for outpatient and smaller facilities. Finally, engage with regional regulatory and reimbursement stakeholders early to clarify access pathways and to align evidence generation with payer expectations. These steps, taken together, help organizations reduce deployment friction, increase clinical confidence, and strengthen commercial positioning across heterogeneous healthcare environments.

A transparent methodology combining primary stakeholder interviews and secondary clinical and regulatory sources to triangulate insights across clinical and procurement domains

The research methodology underpinning this analysis integrated qualitative and quantitative approaches to produce an evidence-informed perspective on clinical practice, procurement trends, and product deployment. Primary research involved structured interviews with clinicians, respiratory therapists, procurement officers, and distribution executives to capture frontline insights into device usability, supply chain challenges, and clinical protocol integration. Secondary sources included peer-reviewed clinical literature, regulatory guidance documents, and published clinical practice standards to ground device and application discussions in accepted medical evidence.

Data synthesis emphasized triangulation across sources to validate observed trends and to illuminate differences in adoption drivers across applications such as adult pulmonary hypertension, ARDS, and neonatal pulmonary hypertension. Segmentation analysis was constructed by mapping product formats, application subtypes, end-user environments, and distribution channels to real-world usage patterns and procurement behaviors. Limitations and caveats were explicitly noted where evidence was evolving or where regional heterogeneity constrained generalization. The methodology prioritizes transparency and reproducibility so that readers can trace conclusions back to source inputs and understand how clinical and operational realities informed final insights.

Conclusions emphasizing clinician-centered design, supply resilience, and collaborative deployment strategies as the foundation for sustained access to inhaled nitric oxide therapies

Inhaled nitric oxide remains an essential and versatile adjunct in the management of several severe respiratory conditions, and its effective deployment depends on aligning product design, clinical protocols, and supply strategies with the realities of care environments. Clinical advances and delivery innovation are expanding where and how iNO can be used, while procurement and regulatory dynamics increasingly shape accessibility and operational readiness. Organizations that adopt a holistic approach-one that integrates technology selection, clinician training, and supply resilience-are better positioned to maintain uninterrupted patient access and to realize the full clinical benefit of this therapy.

Looking ahead, success will hinge on collaborative models that bring together manufacturers, distribution partners, clinical teams, and procurement functions to create tailored solutions for each care setting. By focusing on ease of integration, demonstrable clinical support, and adaptable distribution mechanisms, stakeholders can reduce barriers to adoption and ensure that therapeutic objectives are met across neonatal, adult, and ambulatory care contexts. The conclusions emphasize alignment, resilience, and clinician-centered design as the pillars of sustained access and optimized patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Inhaled Nitric Oxide Market, by Product

  • 8.1. Cylinder
  • 8.2. Generator
  • 8.3. Tanker

9. Inhaled Nitric Oxide Market, by Distribution Channel

  • 9.1. Direct Tender
  • 9.2. Distribution Partner
  • 9.3. Online

10. Inhaled Nitric Oxide Market, by Application

  • 10.1. Adult Pulmonary Hypertension
    • 10.1.1. Idiopathic
    • 10.1.2. Secondary
  • 10.2. Ards
    • 10.2.1. Extracorporeal Membrane Oxygenation
    • 10.2.2. Invasive Ventilation
  • 10.3. Neonatal Pulmonary Hypertension
    • 10.3.1. Extracorporeal Membrane Oxygenation
    • 10.3.2. Mechanical Ventilation

11. Inhaled Nitric Oxide Market, by End User

  • 11.1. Online
  • 11.2. Offline

12. Inhaled Nitric Oxide Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Inhaled Nitric Oxide Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Inhaled Nitric Oxide Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Inhaled Nitric Oxide Market

16. China Inhaled Nitric Oxide Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Air Liquide S.A.
  • 17.6. BOC Ltd.
  • 17.7. Circassia Pharmaceuticals plc
  • 17.8. Ikaria, Inc.
  • 17.9. Linde plc
  • 17.10. Mallinckrodt plc
  • 17.11. Messer Group GmbH
  • 17.12. Novoteris, LLC
  • 17.13. Praxair, Inc.
  • 17.14. VERO Biotech LLC

LIST OF FIGURES

  • FIGURE 1. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INHALED NITRIC OXIDE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INHALED NITRIC OXIDE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INHALED NITRIC OXIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INHALED NITRIC OXIDE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY CYLINDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GENERATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY TANKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION PARTNER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY IDIOPATHIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY SECONDARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY INVASIVE VENTILATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY MECHANICAL VENTILATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 136. GCC INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 140. GCC INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 141. GCC INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. G7 INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. G7 INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. G7 INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 164. G7 INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 165. G7 INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. NATO INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. NATO INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 171. NATO INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 172. NATO INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 173. NATO INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL INHALED NITRIC OXIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES INHALED NITRIC OXIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA INHALED NITRIC OXIDE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA INHALED NITRIC OXIDE MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA INHALED NITRIC OXIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA INHALED NITRIC OXIDE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA INHALED NITRIC OXIDE MARKET SIZE, BY ADULT PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA INHALED NITRIC OXIDE MARKET SIZE, BY ARDS, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA INHALED NITRIC OXIDE MARKET SIZE, BY NEONATAL PULMONARY HYPERTENSION, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA INHALED NITRIC OXIDE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)